Cash Cash Equivalents - NuVasive Inc (F:NK8) - Alpha Spread
N

NuVasive Inc
F:NK8

Watchlist Manager
NuVasive Inc
F:NK8
Watchlist
Price: 36.8 EUR Market Closed
Market Cap: 1.9B EUR
Have any thoughts about
NuVasive Inc?
Write Note

NuVasive Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

NuVasive Inc
Cash & Cash Equivalents Peer Comparison

Comparables:
BDX
BSX
SYK
ABT
ISRG

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
N
NuVasive Inc
F:NK8
Cash & Cash Equivalents
$80.7m
CAGR 3-Years
-53%
CAGR 5-Years
3%
CAGR 10-Years
3%
Becton Dickinson and Co
NYSE:BDX
Cash & Cash Equivalents
$4.5B
CAGR 3-Years
12%
CAGR 5-Years
54%
CAGR 10-Years
10%
Boston Scientific Corp
NYSE:BSX
Cash & Cash Equivalents
$2.9B
CAGR 3-Years
3%
CAGR 5-Years
88%
CAGR 10-Years
23%
Stryker Corp
NYSE:SYK
Cash & Cash Equivalents
$1.9B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
4%
Abbott Laboratories
NYSE:ABT
Cash & Cash Equivalents
$7B
CAGR 3-Years
-7%
CAGR 5-Years
17%
CAGR 10-Years
7%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash & Cash Equivalents
$3B
CAGR 3-Years
23%
CAGR 5-Years
31%
CAGR 10-Years
20%

See Also

What is NuVasive Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
80.7m USD

Based on the financial report for Jun 30, 2023, NuVasive Inc's Cash & Cash Equivalents amounts to 80.7m USD.

What is NuVasive Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
3%

Over the last year, the Cash & Cash Equivalents growth was -64%. The average annual Cash & Cash Equivalents growth rates for NuVasive Inc have been -53% over the past three years , 3% over the past five years , and 3% over the past ten years .

Back to Top